Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$404.91 USD
+4.06 (1.01%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $403.03 -1.88 (-0.46%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Vertex Pharmaceuticals (VRTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$451.69 | $559.00 | $325.00 | 12.95% |
Price Target
Based on short-term price targets offered by 26 analysts, the average price target for Vertex Pharmaceuticals comes to $451.69. The forecasts range from a low of $325.00 to a high of $559.00. The average price target represents an increase of 12.95% from the last closing price of $399.92.
Analyst Price Targets (26)
Broker Rating
Vertex Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.87 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 30 brokerage firms. The current ABR compares to an ABR of 1.93 a month ago based on 28 recommendations.
Of the 30 recommendations deriving the current ABR, 19 are Strong Buy, representing 63.33% of all recommendations. A month ago, Strong Buy represented 60.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 17 | 17 | 17 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 9 | 9 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 1.87 | 1.87 | 1.93 | 1.93 | 1.89 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | Canaccord Genuity | Whitney Ijem | Strong Sell | Strong Sell |
4/11/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
4/11/2024 | Evercore Partners | Liisa A Bayko | Hold | Strong Buy |
4/11/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/1/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
3/10/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
2/6/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1/31/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Strong Sell |
1/30/2024 | Maxim Group | Naz Rahman | Strong Buy | Hold |
1/3/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
12/14/2023 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
11/10/2023 | Not Identified | Not Identified | Hold | Hold |
11/7/2023 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
11/6/2023 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.87 |
ABR (Last week) | 1.87 |
# of Recs in ABR | 30 |
Average Target Price | $451.69 |
LT Growth Rate | 14.20% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | 4.10 |